vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Employers Holdings, Inc. (EIG). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $170.5M, roughly 1.7× Employers Holdings, Inc.). On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -21.3%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -11.4%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Employers Holdings, Inc. is a U.S.-headquartered insurance holding company that specializes in offering workers' compensation insurance and customized risk management services primarily for small and medium-sized enterprises across the United States. It mainly serves clients in low-to-medium hazard industries, helping them mitigate workplace safety risks and meet relevant regulatory requirements for employee protection.
ACAD vs EIG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $170.5M |
| Net Profit | $273.6M | — |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | — |
| Net Margin | 96.3% | — |
| Revenue YoY | 9.4% | -21.3% |
| Net Profit YoY | 90.3% | — |
| EPS (diluted) | $1.61 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $170.5M | ||
| Q4 25 | $284.0M | $188.5M | ||
| Q3 25 | $278.6M | $239.3M | ||
| Q2 25 | $264.6M | $246.3M | ||
| Q1 25 | $244.3M | $202.6M | ||
| Q4 24 | $259.6M | $216.6M | ||
| Q3 24 | $250.4M | $224.0M | ||
| Q2 24 | $242.0M | $217.0M |
| Q1 26 | — | — | ||
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | $-8.3M | ||
| Q2 25 | $26.7M | $29.7M | ||
| Q1 25 | $19.0M | $12.8M | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | $30.3M | ||
| Q2 24 | $33.4M | $31.7M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | -4.7% | ||
| Q2 25 | 12.2% | 15.0% | ||
| Q1 25 | 7.9% | 7.8% | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | 16.4% | ||
| Q2 24 | 12.6% | 18.4% |
| Q1 26 | — | — | ||
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | -3.5% | ||
| Q2 25 | 10.1% | 12.1% | ||
| Q1 25 | 7.8% | 6.3% | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | 13.5% | ||
| Q2 24 | 13.8% | 14.6% |
| Q1 26 | — | — | ||
| Q4 25 | $1.61 | $-0.93 | ||
| Q3 25 | $0.42 | $-0.36 | ||
| Q2 25 | $0.16 | $1.23 | ||
| Q1 25 | $0.11 | $0.52 | ||
| Q4 24 | $0.86 | $1.14 | ||
| Q3 24 | $0.20 | $1.21 | ||
| Q2 24 | $0.20 | $1.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $169.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $955.7M |
| Total Assets | $1.6B | $3.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $169.9M | ||
| Q4 25 | $177.7M | $169.9M | ||
| Q3 25 | $258.0M | $172.4M | ||
| Q2 25 | $253.6M | $78.1M | ||
| Q1 25 | $217.7M | $100.4M | ||
| Q4 24 | $319.6M | $68.4M | ||
| Q3 24 | $155.1M | $173.9M | ||
| Q2 24 | $177.1M | $126.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $19.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $955.7M | ||
| Q4 25 | $1.2B | $955.7M | ||
| Q3 25 | $917.3M | $1.0B | ||
| Q2 25 | $822.4M | $1.1B | ||
| Q1 25 | $765.2M | $1.1B | ||
| Q4 24 | $732.8M | $1.1B | ||
| Q3 24 | $577.2M | $1.1B | ||
| Q2 24 | $516.7M | $1.0B |
| Q1 26 | — | $3.4B | ||
| Q4 25 | $1.6B | $3.4B | ||
| Q3 25 | $1.3B | $3.5B | ||
| Q2 25 | $1.2B | $3.5B | ||
| Q1 25 | $1.1B | $3.6B | ||
| Q4 24 | $1.2B | $3.5B | ||
| Q3 24 | $976.9M | $3.6B | ||
| Q2 24 | $914.1M | $3.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $44.7M | ||
| Q3 25 | $74.3M | $29.4M | ||
| Q2 25 | $64.0M | $0 | ||
| Q1 25 | $20.3M | $14.6M | ||
| Q4 24 | $40.4M | $76.4M | ||
| Q3 24 | $63.2M | $51.0M | ||
| Q2 24 | $25.0M | $11.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $44.6M | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $76.3M | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 23.7% | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 35.2% | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | 0.00× | ||
| Q1 25 | 1.07× | 1.14× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 1.68× | ||
| Q2 24 | 0.75× | 0.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
EIG
Segment breakdown not available.
